Ionis Pharmaceuticals INC
Forward trial catalysts linked to IONS
CSA tracks 2 forward catalysts for Ionis Pharmaceuticals INC across 2 assets, spanning Phase 3. The nearest is a readout expected Dec 2026 (month precision). Confidence across its tracked catalysts breaks down as 2 medium. Tracked indications include Hereditary Angioedema, Hereditary Angioedema (HAE), Severe Hypertriglyceridemia.
IONS in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Ionis Pharmaceuticals INC has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
3 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| donidalorsen | NCT05392114 catalyst | Phase 3 | Active, not recruiting | 2026-12 | Experimental | Ionis Pharmaceuticals, Inc. | Hereditary Angioedema |
| olezarsen | NCT05681351 catalyst | Phase 3 | Active, not recruiting | 2027-03 | Experimental | Ionis Pharmaceuticals, Inc. | Severe Hypertriglyceridemia |
| donidalorsen | NCT07298447 | Phase 3 | Recruiting | 2029-06 | Experimental | Ionis Pharmaceuticals, Inc. | Hereditary Angioedema (HAE) |
Every trial the CSA sample links to IONS's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →